INBS falls despite completing clinical study for FDA approval

INBS stock plummeted nearly 20% in premarket trading despite announcing successful results from its initial clinical trial. The company is seeking FDA approval for its fingerprint-based drug-testing system. While the study confirmed the device's accuracy in detecting codeine, the update failed to lift investor sentiment. INBS plans to complete the second phase of its program by June 2026.